Literature DB >> 11041404

Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

S E Cowper, H S Robin, S M Steinberg, L D Su, S Gupta, P E LeBoit.   

Abstract

15 renal dialysis patients have been identified with a skin condition characterised by thickening and hardening of the skin of the extremities and an increase in dermal fibroblast-like cells associated with collagen remodelling and mucin deposition. The disease closely resembles scleromyxoedema, yet has significant enough clinical and histopathological differences to warrant its designation as a new clinicopathological entity.

Entities:  

Mesh:

Year:  2000        PMID: 11041404     DOI: 10.1016/S0140-6736(00)02694-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  157 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

2.  Non-contrast MRA using an inflow-enhanced, inversion recovery SSFP technique in pediatric abdominal imaging.

Authors:  Suraj Serai; Alexander J Towbin; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2011-11-10

3.  Magnetic resonance angiography (MRA) of the calf station at 3.0 T: intraindividual comparison of non-enhanced ECG-gated flow-dependent MRA, continuous table movement MRA and time-resolved MRA.

Authors:  Stefan Haneder; Ulrike I Attenberger; Philipp Riffel; Thomas Henzler; Stefan O Schoenberg; Henrik J Michaely
Journal:  Eur Radiol       Date:  2011-01-28       Impact factor: 5.315

Review 4.  Tyrosine kinases in inflammatory dermatologic disease.

Authors:  Ricardo T Paniagua; David F Fiorentino; Lorinda Chung; William H Robinson
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

5.  Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.

Authors:  Ti-Yung Tseng; Jeng-Hwei Tseng; Bing-Shen Huang; Shen-Yen Lin; Chun-Bing Chen; Yi-Wen Fang; Gigin Lin; Ying-Chieh Lai
Journal:  Abdom Radiol (NY)       Date:  2021-03-20

Review 6.  [Complications due to contrast agent administration: what has been confirmed in prevention?].

Authors:  E Schönenberger; M Mühler; M Dewey
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

7.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

8.  [Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging].

Authors:  C Giersig
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

9.  [Nephrogenic systemic fibrosis].

Authors:  W Samtleben
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

10.  Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.

Authors:  Emmanuil Smorodinsky; David S Ansdell; Zeke W Foster; Sameer M Mazhar; Irene Cruite; Tanya Wolfson; Sebastian B Sugay; Gabriella Iussich; Masoud Shiehmorteza; Yuko Kono; Alexander Kuo; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2014-05-09       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.